Evidence map›Paper›PMID 33598888›Full record

ArticleCanadian journal of anaesthesia = Journal canadien d'anesthesie2021

Intravenous immune globulin in septic shock: a Canadian national survey of critical care medicine and infectious disease specialist physicians.

Murdoch Leeies, Hayley B Gershengorn, Emmanuel Charbonney, Anand Kumar, Dean Fergusson, Alexis F Turgeon, Juthaporn Cowan, Bojan Paunovic, John Embil, Allan Garland and 9 more

Erratum issuedOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 2 countries.

Murdoch LeeiesDepartment of Emergency Medicine, Section of Critical Care Medicine, University of Manitoba, Winnipeg, MB, Canada. mleeies@hsc.mb.ca.ORCID http://orcid.org/0000-0002-7645-0791
Hayley B GershengornDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Miami, Miami, FL, USA.
Emmanuel CharbonneyDepartment of Medicine, Critical Care, Université de Montréal, Montreal, QC, Canada.
Anand KumarDepartment of Medical Microbiology, Section of Critical Care Medicine, University of Manitoba, Winnipeg, MB, Canada.
Dean FergussonDepartments of Medicine, Surgery, Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
Alexis F TurgeonCHU de Québec - Université Laval Research Center, Population Health and Optimal Health Practices Research Unit (Trauma-Emergency-Critical Care Medicine), Québec City, QC, Canada.
Juthaporn CowanDivision of Infectious Diseases, Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Bojan PaunovicDepartment of Medicine, Section of Critical Care Medicine, University of Manitoba, Winnipeg, MB, Canada.
John EmbilDepartment of Medicine, Section of Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada.
Allan GarlandDepartment of Medicine, Section of Critical Care Medicine, University of Manitoba, Winnipeg, MB, Canada.
Donald S HoustonDepartment of Medical Oncology & Hematology, Cancercare Manitoba, Winnipeg, MB, Canada.
Brett HoustonDepartment of Medical Oncology & Hematology, Cancercare Manitoba, Winnipeg, MB, Canada.
Emily RimmerDepartment of Medical Oncology & Hematology, Cancercare Manitoba, Winnipeg, MB, Canada.
Faisal SiddiquiDepartment of Anesthesiology, Section of Critical Care Medicine, University of Manitoba, Winnipeg, MB, Canada.
Bill CameronOttawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
Srinivas MurthyDepartment of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
John C MarshallDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Rob FowlerDepartment of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Ryan ZarychanskiDepartment of Medicine, Section of Critical Care Medicine, University of Manitoba, Winnipeg, MB, Canada.
University of Manitoba · CACancerCare Manitoba · CAUniversity of Ottawa · CAAlbert Einstein College of Medicine · USSunnybrook Health Science Centre · CAThe Quebec Population Health Research Network · CAUniversité de Montréal · CAUniversity of British Columbia · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis national survey evaluated the perceived efficacy and safety of intravenous immune globulin (IVIG) in septic shock, self-reported utilization patterns, barriers to use, the population of interest for further trials and willingness to participate in future research of IVIG in septic shock.

methodsWe conducted a cross-sectional survey of critical care and infectious diseases physicians across Canada. We summarized categorical item responses as counts and proportions. We developed a multivariable logistic regression model to identify physician-level predictors of IVIG use in septic shock.

resultsOur survey was disseminated to 674 eligible respondents with a final response rate of 60%. Most (91%) respondents reported having prescribed IVIG to patients with septic shock at least once, 86% for septic shock due to necrotizing fasciitis, 52% for other bacterial toxin-mediated causes of septic shock, and 5% for undifferentiated septic shock. The majority of respondents expressed uncertainty regarding the impact of IVIG on mortality (97%) and safety (95%) in septic shock. Respondents were willing to participate in further IVIG research with 98% stating they would consider enrolling their patients into a trial of IVIG in septic shock. Familiarity with published evidence was the single greatest predictor of IVIG use in septic shock (odds ratio, 10.2; 95% confidence interval, 3.4 to 30.5; P < 0.001).

conclusionsMost Canadian critical care and infectious diseases specialist physicians reported previous experience using IVIG in septic shock. Respondents identified inadequacy of existing research as the greatest barrier to routine use of IVIG in septic shock. Most respondents support the need for further studies on IVIG in septic shock, and would consider enrolling their own patients into a trial of IVIG in septic shock.

Indexed as

Communicable DiseasesPhysiciansSepsisShock, SepticCanadaCritical CareCross-Sectional StudiesHumansImmunoglobulins, IntravenousImmunoglobulins, Intravenousimmunomodulationintravenous immune globulinIVIGsepsisseptic shock

Identifiers

PMID33598888
OpenAlexW4205561958

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.